ChemicalBook > CAS DataBase List > CIVENTICHEM CV-4057

CIVENTICHEM CV-4057

Product Name
CIVENTICHEM CV-4057
CAS No.
248281-84-7
Chemical Name
CIVENTICHEM CV-4057
Synonyms
LAQ;CS-82;ABR 215062;ABR-215062;Lanquinimod;CIVENTICHEM;oro-N-ethyL;-2-oxo-N-phenyL;Laquinimod, >=98%;ine-3-carboxamide
CBNumber
CB7836628
Molecular Formula
C19H17ClN2O3
Formula Weight
356.8
MOL File
248281-84-7.mol
More
Less

CIVENTICHEM CV-4057 Property

Melting point:
201 °C (decomp)
Boiling point:
484.8±45.0 °C(Predicted)
Density 
1.395±0.06 g/cm3(Predicted)
storage temp. 
Sealed in dry,Room Temperature
solubility 
Soluble in DMSO (>25 mg/ml)
form 
solid
pka
4.50±1.00(Predicted)
color 
Off-white
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
More
Less

Safety

Hazard Codes 
T
Risk Statements 
25
Safety Statements 
45
RIDADR 
UN 2811 6.1 / PGIII
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H301Toxic if swalloed

Precautionary statements

P301+P310IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML2504
Product name
Laquinimod
Purity
≥98% (HPLC)
Packaging
10MG
Price
$62.51
Updated
2025/07/31
Sigma-Aldrich
Product number
SML2504
Product name
Laquinimod
Purity
≥98% (HPLC)
Packaging
50MG
Price
$235.9
Updated
2025/07/31
Sigma-Aldrich
Product number
CVT00095
Product name
5-Chloro-N-Et-4-hydroxy-1-methyl-2-oxo-N-Ph-1,2-dihydroquinoline-3-carboxamide
Packaging
1g
Price
$747
Updated
2025/07/31
TCI Chemical
Product number
L0427
Product name
Laquinimod
Packaging
100MG
Price
$108
Updated
2025/07/31
Cayman Chemical
Product number
24187
Product name
Laquinimod
Purity
≥98%
Packaging
100mg
Price
$73
Updated
2024/03/01
More
Less

CIVENTICHEM CV-4057 Chemical Properties,Usage,Production

Description

Laquinimod (248281-84-7) is an immunomodulator1 that inhibits inflammation2 and autoimmunity3,4 via activation of the aryl hydrocarbon receptor (AhR)5. It has been investigated as a treatment for multiple sclerosis6 and has shown efficacy in Huntington’s disease models7,8.

Uses

Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has?the?potential?for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases?research[1][2][3][4].

Definition

ChEBI: Laquinimod is an aromatic amide.

Synthesis

1379595-99-9

248281-84-7

b) To a stirred solution of anhydrous tetrahydrofuran (50 mL) of the compound (CAS:1379595-99-9) (10 mmol) was added sodium methanolate (3.6 mmol, 0.5 M, dissolved in methanol) in batches under nitrogen protection. The reaction mixture was heated to reflux for 2 hours. Upon completion of the reaction, the mixture was cooled and the solvent was partially evaporated to give a concentrated solution containing the insoluble salt. The concentrated solution was dissolved in a solvent mixture of methanol (30 mL), 10 M aqueous sodium hydroxide (1.07 mL, 10.7 mmol) and water (15.0 mL). Subsequently, 5 M aqueous hydrochloric acid (2.4 mL, 12.0 mmol) was slowly added to neutralize the reaction mixture. The precipitated crystalline precipitate was collected by filtration, washed with cold methanol and dried to afford the target product 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide in 87% yield and 98.9% purity.

in vitro

abr-215062 was shown to completely inhibit the development of murine acute experimental autoimmune encephalomyelitis (eae) [1].

in vivo

abr-215062 dose-dependently inhibited disease and showed better disease inhibitory effects as compared to roquinimex (linomide). furthermore, abr-215062 inhibited the inflammation of both cd4+ t cells and macrophages into central nervous tissues [2].

IC 50

NF-κB

References

[1] STIG JÖNSSON. Synthesis and Biological Evaluation of New 1,2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for Treatment of Autoimmune Disorders: Structure−Activity Relationship[J]. Journal of Medicinal Chemistry, 2004, 47 8: 2075-2088. DOI:10.1021/jm031044w
[2] VEIT ROTHHAMMER. Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS.[J]. Neurology(R) neuroimmunology & neuroinflammation, 2021. DOI:10.1212/nxi.0000000000000946
[3] KALLIOPI PITAROKOILI . Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis[J]. Journal of neuroimmunology, 2014, 274 1: Pages 38-45. DOI:10.1016/j.jneuroim.2014.06.012
[4] MARTINA OTT. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.[J]. Journal of Neuroinflammation, 2019: 49. DOI:10.1186/s12974-019-1437-0
[5] J. KAYE. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor[J]. Proceedings of the National Academy of Sciences, 2016, 27 1: E6145-E6152. DOI:10.1073/pnas.1607843113
[6] J. THÖNE R L. Laquinimod in the treatment of multiple sclerosis: a review of the data so far[J]. Drug Design, Development and Therapy, 2016, 10 1: 1111-1118. DOI:10.2147/dddt.s55308
[7] LUCIANNE DOBSON. Laquinimod dampens hyperactive cytokine production in Huntington’s disease patient myeloid cells[J]. Journal of Neurochemistry, 2016, 137 5: 782-794. DOI:10.1111/jnc.13553
[8] MARTA GARCIA-MIRALLES. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.[J]. Scientific Reports, 2016: 31652. DOI:10.1038/srep31652

CIVENTICHEM CV-4057 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

CIVENTICHEM CV-4057 Suppliers

Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
JinYan Chemicals(ShangHai) Co.,Ltd.
Tel
13817811078
Fax
86-021-50426522,50426273
Email
sales@jingyan-chemical.com
Country
China
ProdList
9976
Advantage
60
Shanghai Hanhong Scientific Co.,Ltd.
Tel
021-54306202 13764082696
Email
info@hanhongsci.com
Country
China
ProdList
42934
Advantage
64
Hangzhou Yuhao Chemical Technology Co., Ltd
Tel
0571-82693216
Fax
+86-571-82880190
Email
info@yuhaochemical.com
Country
China
ProdList
6387
Advantage
52
Shanghai Sphchem Co., Ltd.
Tel
021-56491756 13512199871
Fax
021-5649-1756
Email
2819742715@qq.com
Country
China
ProdList
4000
Advantage
55
Hangzhou Sage Chemical Co., Ltd.
Tel
+86057186818502 13588463833
Fax
Pls mail us for more information!
Email
info@sagechem.com
Country
China
ProdList
10266
Advantage
58
Tianjin YongSheng Biotechnology Co., Ltd.
Tel
022-60987737 13512258274
Fax
86-022-23500597
Email
sales@immortalbio.com
Country
China
ProdList
154
Advantage
55
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12335
Advantage
58
NCE Biomedical Co.,Ltd.
Tel
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
Fax
+86-27-87599188
Country
China
ProdList
1493
Advantage
55
Nanjing Norris-Pharm Technology Co., Ltd
Tel
18652989687
Fax
+86-25-52131256
Email
sales@norris-pharm.com
Country
China
ProdList
8878
Advantage
55

248281-84-7, CIVENTICHEM CV-4057Related Search:


  • CIVENTICHEM CV-4057
  • LAQUINIMOD,5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-1,2-DIHYDRO-QUINOLINE-3-CARBOXYLIC ACID ETHYL-PHENYL-AMIDE
  • ABR-215062 (Laquinimod)
  • CIVENTICHEM
  • CS-82
  • ABR215062; ABR 215062 (LAQUINIMOD)
  • 5-Chloro-4-hydroxy-1-Methyl-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid ethyl-phenyl-aMide
  • LaquiniMod, SAIK-MS coMpound, ABR-215062
  • 5-Chloro-4-hydroxy-1-methyl-2-oxo-N-ethyl-N-phenyl-1,2-dihydroquinoline-3-carboxamide
  • Lanquinimod
  • LaquiniMod,CiventicheMCV-4057,5-Chloro-4-hydroxy-1-Methyl-2-oxo-1,2-dihydroquinoline-3-carboxylicacidethylphenylaMide
  • 5-chloro-N-ethyl-4-hydroxy-1-Methyl-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxaMide
  • ABR 215062
  • ABR-215062
  • LaquiniMod (ABR-215062)
  • LAQ
  • Laquinimod potassium salt
  • 5-Chloro-N-Et-4-hydroxy-1-methyl-2-oxo-N-Ph-1,2-dihydroquinoline-3-carboxamide
  • Laquinimod, >=98%
  • 5-chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenylquinoline-3-carboxamide
  • -1,2-dihydroquinoL
  • -2-oxo-N-phenyL
  • -4-hydroxy-1-methyL
  • ine-3-carboxamide
  • oro-N-ethyL
  • 3-Quinolinecarboxamide, 5-chloro-N-ethyl-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-N-phenyl-
  • 5-Chloro-N-ethyl-4-hydroxy-1-methyl-2-oxo-N-phenyl-1,2-dihyd...
  • inhibit,multiple sclerosis,relapsing remitting,carboxamide,Nuclear factor-kappaB,Apoptosis,Inhibitor,ABR 215062,Nuclear factor-κB,immunomodulator,ABR215062,chronic progressive,neurodegenerative disease,inflammation,NF-κB,Laquinimod,Orally,neurodegeneration
  • Laquinimod, 10 mM in DMSO
  • 5-Chloro-<i>N</i>-Et-4-hydroxy-1-methyl-2-oxo-<i>N</i>-Ph-1,2-dihydroquinoline-3-carboxamide
  • 248281-84-7
  • Inhibitors
  • api
  • Heterocycles